SCHEMBL333665

SCHEMBL333665

CN(C)c1ccc(-n2c(CC(=O)O)c(C(=O)O)c3cc(Oc4ccc(OC(F)(F)F)cc4)ccc32)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
ATM Q13315 1/20 0.44
PPARG P37231 5/20 0.42
PPARA Q07869 2/20 0.42
KDM4E B2RXH2 1/20 0.38
CACNA1G O43497 1/20 0.37
CACNA1H O95180 1/20 0.37
CACNA1I Q9P0X4 1/20 0.37
USP14 P54578 1/20 0.37
PTGDR2 Q9Y5Y4 2/20 0.36
GCGR P47871 1/20 0.35
RAB9A P51151 1/20 0.35
ELANE P08246 1/20 0.35
PLA2G4A P47712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL333566 0.91 PPARG (0.41) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL334110 0.91 MEN1 (0.44) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL10076916 0.89 PPARG (0.47) MEN1KMT2AALDH1A1MAPTPPARG
SCHEMBL503512 0.89 PPARG (0.43) MEN1KMT2AALDH1A1MAPTPPARG
SCHEMBL333774 0.88 PPARG (0.46) MEN1KMT2APPARGPPARAPLA2G4A
SCHEMBL333611 0.88 PPARG (0.47) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL504356 0.87 PPARG (0.42) MEN1KMT2AMAPTPPARGPPARA
SCHEMBL361319 0.87 PPARG (0.42) MEN1KMT2AMAPTPPARGPPARA
SCHEMBL333656 0.87 PPARG (0.43) MEN1KMT2AMAPTPPARGPPARA
SCHEMBL504095 0.86 KDM4C (0.38) MEN1KMT2APPARGPPARAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097623-B2 1-Aryl-or heteroaryl-3-aryl-or heteroarylindole-2-carboxylic acids or esters: e.g., 5-(4-tert-Butylphenyl)-1,3-bis(4-isopropoxyphenyl)-indole-2-carboxylic acid; inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C4 and/or 5-lipoxygenase-activating protein; analgesics BIOLIPOX AB (SE) 2012-01-17 US disclosed
EP-1841735-B1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2011-03-09 EP disclosed
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation IDO1, IDO2, AREG MEN1 2066/4885KMT2A 3484/4885ALDH1A1 2276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.